CrossingBio: The Latest SDU Spinout Aiming to Transform Liver Fibrosis Treatment
CrossingBio is the newest addition to the growing portfolio of life science spinouts from the University of Southern Denmark (SDU). The company is developing a new therapeutic approach for liver fibrosis, a condition affecting millions of people worldwide and still difficult to treat effectively.
Strong research and funding foundation
CrossingBio builds on more than 12 years of research at SDU’s Faculty of Health Sciences and has already attracted €4.5 million in funding, demonstrating both the strength of the underlying science and the potential of the developed therapies.
“CrossingBio demonstrates what is possible when strong research is combined with a clear mission to create real patient value. It shows how dedicated scientists can translate years of fundamental research into tangible solutions that address pressing medical needs. By bringing together scientific expertise, strategic funding, and a commercial perspective, CrossingBio is not only advancing innovative therapies but also contributing to the growth and reputation of Odense as a hub for life science excellence.”
A key strategic element is the appointment of CEO Mads Aaboe Jensen, who comes from outside the research environment. This allows the scientific founders to focus on product development while the CEO drives business strategy, partnerships, and commercialization.
Promising indication
One of the most promising indications for CrossingBio’s therapy is biliary atresia, a rare pediatric disease that currently has very limited treatment options. The therapy aims to delay or potentially prevent the need for liver transplantation, offering a significant clinical benefit to affected children.
Part of SDU’s growing spinout ecosystem
CrossingBio is part of a growing wave of life science spinouts emerging from SDU, illustrating how strong academic research can be successfully translated into impactful companies. These spinouts are increasingly contributing to the Odense life science ecosystem, creating jobs, attracting investment, and strengthening the region’s reputation as a hub for medical innovation.
“SDU’s life science spinouts have huge potential and are showing strong progress. The spinouts we have seen combine solid research with strong teams, and CrossingBio is an excellent example of this momentum.”
CrossingBio is now moving toward clinical development. The company represents not only hope for patients with liver fibrosis but also a key contributor to Odense’s growing life science community, helping to position the city as a center for innovation and medical breakthroughs.
Further information
Lone Krogsbøll
Investment Manager - Life Science
I help foreign companies in the biotech and life science industry to establish in Odense and connect them to relevant business partners and opportunities here. My background is in health tech, but I’ve focused on broader life science sectors since 2018.
+45 5177 7344
loak@odense.dk
Connect
